These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26177543)

  • 1. The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?
    Pagano S; Gaertner H; Cerini F; Mannic T; Satta N; Teixeira PC; Cutler P; Mach F; Vuilleumier N; Hartley O
    PLoS One; 2015; 10(7):e0132780. PubMed ID: 26177543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.
    Teixeira PC; Ducret A; Ferber P; Gaertner H; Hartley O; Pagano S; Butterfield M; Langen H; Vuilleumier N; Cutler P
    J Biol Chem; 2014 Oct; 289(41):28249-59. PubMed ID: 25170076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction.
    Rubini Gimenez M; Pagano S; Virzi J; Montecucco F; Twerenbold R; Reichlin T; Wildi K; Grueter D; Jaeger C; Haaf P; Vuilleumier N; Mueller C
    Eur J Clin Invest; 2015 Apr; 45(4):369-79. PubMed ID: 25627775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study.
    Antiochos P; Marques-Vidal P; Virzi J; Pagano S; Satta N; Bastardot F; Hartley O; Montecucco F; Mach F; Waeber G; Vollenweider P; Vuilleumier N
    Thromb Haemost; 2016 Sep; 116(4):764-71. PubMed ID: 27384400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex.
    Pagano S; Satta N; Werling D; Offord V; de Moerloose P; Charbonney E; Hochstrasser D; Roux-Lombard P; Vuilleumier N
    J Intern Med; 2012 Oct; 272(4):344-57. PubMed ID: 22329401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction.
    Keller PF; Pagano S; Roux-Lombard P; Sigaud P; Rutschmann OT; Mach F; Hochstrasser D; Vuilleumier N
    J Intern Med; 2012 May; 271(5):451-62. PubMed ID: 22061093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus.
    El-Lebedy D; Rasheed E; Kafoury M; Abd-El Haleem D; Awadallah E; Ashmawy I
    J Diabetes Complications; 2016; 30(4):580-5. PubMed ID: 26965796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of lipid-binding properties of the N-terminal helical segments in human apolipoprotein A-I using fragment peptides.
    Tanaka M; Tanaka T; Ohta S; Kawakami T; Konno H; Akaji K; Aimoto S; Saito H
    J Pept Sci; 2009 Jan; 15(1):36-42. PubMed ID: 19048603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives.
    Teixeira PC; Cutler P; Vuilleumier N
    Clin Dev Immunol; 2012; 2012():868251. PubMed ID: 23227091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage.
    Pruijm M; Schmidtko J; Aho A; Pagano S; Roux-Lombard P; Teta D; Burnier M; Vuilleumier N
    Ther Apher Dial; 2012 Dec; 16(6):588-94. PubMed ID: 23190520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability.
    Montecucco F; Vuilleumier N; Pagano S; Lenglet S; Bertolotto M; Braunersreuther V; Pelli G; Kovari E; Pane B; Spinella G; Pende A; Palombo D; Dallegri F; Mach F; Roux-Lombard P
    Eur Heart J; 2011 Feb; 32(4):412-21. PubMed ID: 21224292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural autoantibody against apolipoprotein A-I. Detection and characterization of the monoclonal antibody established from normal unimmunized BALB/c mice.
    Imai H; Suzuki S; Uchida K; Kikuchi K; Sugiyama H; Kohno H; Umeda M; Inoue K
    J Immunol; 1994 Sep; 153(5):2290-301. PubMed ID: 8051425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I.
    Tanaka M; Koyama M; Dhanasekaran P; Nguyen D; Nickel M; Lund-Katz S; Saito H; Phillips MC
    Biochemistry; 2008 Feb; 47(7):2172-80. PubMed ID: 18205410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction.
    Vuilleumier N; Rossier MF; Pagano S; Python M; Charbonney E; Nkoulou R; James R; Reber G; Mach F; Roux-Lombard P
    Eur Heart J; 2010 Apr; 31(7):815-23. PubMed ID: 20176799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report.
    Henson D; Tahhan AS; Nardo D; Quyyumi AA; Venditto VJ
    Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1884-1892. PubMed ID: 31315438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined N- and C-terminal truncation of human apolipoprotein A-I yields a folded, functional central domain.
    Beckstead JA; Block BL; Bielicki JK; Kay CM; Oda MN; Ryan RO
    Biochemistry; 2005 Mar; 44(11):4591-9. PubMed ID: 15766290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation and lipid binding of the N-terminal (1-44) domain of human apolipoprotein A-I.
    Zhu HL; Atkinson D
    Biochemistry; 2004 Oct; 43(41):13156-64. PubMed ID: 15476409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients.
    Satta N; Pagano S; Montecucco F; Gencer B; ; Mach F; Kaiser L; Calmy A; Vuilleumier N
    J Infect; 2018 Feb; 76(2):186-195. PubMed ID: 29198606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro.
    Ingenito R; Burton C; Langella A; Chen X; Zytko K; Pessi A; Wang J; Bianchi E
    Bioorg Med Chem Lett; 2010 Jan; 20(1):236-9. PubMed ID: 19932961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The helix-hinge-helix structural motif in human apolipoprotein A-I determined by NMR spectroscopy.
    Wang G; Sparrow JT; Cushley RJ
    Biochemistry; 1997 Nov; 36(44):13657-66. PubMed ID: 9354635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.